News | May 27, 2026
Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz
The company highlighted continued demand strength and pricing resilience despite global disruptions
The company highlighted continued demand strength and pricing resilience despite global disruptions
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
Subscribe To Our Newsletter & Stay Updated
